Obsessive-Compulsive Disorder
Updated: 06/30/2006

References

Altemus M, Greenberg BD et al. Open trial of flutamide for treatment of obsessive-compulsive disorder. J Clin Psychiatry. 1999 Jul;60(7):442–5.

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Press; 2004.

Arnold PD, Richter MA. Is obsessive-compulsive disorder an autoimmune disease? CMAJ. 2001 Nov 13;165(10):1353–58.

Barr LC, Goodman WK et al. Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Arch Gen Psychiatry. 1994 Apr;51(4):309–17.

Bell C, Abrams J et al. Tryptophan depletion and its implications for psychiatry. Br J Psychiatry. 2001 May;178:399–405.

Benson H, Frankel FH et al. Treatment of anxiety: A comparison of the usefulness of self-hypnosis and a meditational relaxation technique: An overview. Psychother Psychosom. 1978;30(3-4):229–42.

Berney A, Sookman D et al. Lack of effects on core obsessive-compulsive symptoms of tryptophan depletion during symptom provocation in remitted obsessive-compulsive disorder patients. Biol Psychiatry. 2006 May 1;59(9):853–7.

Brown RP, Gerbarg PL. Sudarshan Kriya Yogic breathing in the treatment of stress, anxiety, and depression. Part II—clinical applications and guidelines. J Altern Complement Med. 2005 Aug;11(4):711–7.

Calvocoressi L, Lewis B et al. Family accommodation in obsessive-compulsive disorder. Am J Psychiatry. 1995;152:441.

Cosoff S, Hafner RJ. The prevalence of comorbid anxiety in schizophrenia, schizoaffective disorder, and bipolar disorder. Aust N Z J Psychiatry. 1998;32:67–72.

Eriksson, T. Antiandrogenic treatment for obsessive-compulsive disorder. Letters to the editor. Am J Psychiatry. Mar 2000;157:483.

Fiebich BL, Hollig A et al. Inhibition of substance P-induced cytokine synthesis by St. John’s wort extracts. Pharmacopsychiatry. 2001 Jul;34 Supp 1:S26–S28.

Hu XZ, Lipsky RH et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Human Genetics. 2006 May;78(5):815–26.

Herzog AG. Psychoneuroendocrine aspects of temporolimbic epilepsy: Part I: Brain, reproductive steroids, and emotions. Psychosomatics. 1999 Mar-Apr;40(2):95–101.

Himle JA, Rassi S et al. Group behavioral therapy of obsessive-compulsive disorder: Seven vs. twelve-week outcomes. Depress Anxiety. 2001;13(4):161–5.

Hollander E, Stein D et al. Psychosocial function and economic costs of obsessive-compulsive disorder. CNS Spectrums. 1997;2:16.

Huwig-Poppe C, Voderholzer U et al. The tryptophan depletion test: Impact on sleep in healthy subjects and patients with obsessive-compulsive disorder. Adv Exp Med Biol. 1999;467:35–42.

Juneja LR, Chu D-C et al. L-theanine a unique amino acid of green tea and its relaxation effect in humans. Trends Food Sci Tech. 1999;10:199–204.

Kakuda T, Nozawa A et al. Inhibiting effects of theanine on caffeine stimulation evaluated by EEG in the rat. Biosci Biotechno Biochem. 2000;64:287–93.

Koran LM. Quality of life in obsessive-compulsive disorder. Psychiatr Clin North Am. 2000;23:509–617.

Koran LM, Thienemann ML et al. Quality of life for patients with obsessive-compulsive disorder. Am J Psychiatry. 1996;153:783–8.

Kruger S, Cooke RG et al. Comorbidity of obsessive compulsive disorder in bipolar disorder. J Affective Disord. 1995;34:117–20.

Levine J. Controlled trials of inositol in psychiatry. Eur Neuropsychopharmacol. 1997 May;7(2):147–55.

Monteleone P, Catapano F et al. Plasma melatonin and cortisol circadian patterns in patients with obsessive-compulsive disorder before and after fluoxetine treatment. Psychoneuroendocrinology. 1995;20(7):763–70.

Nestadt G, Samuels J et al. A family study of obsessive-compulsive disorder. Arch Gen Psychiatry. 2000 Apr;57(4):358–63.

National Institute of Mental Health 2006. Facts about Obsessive-Compulsive Disorder. Available at: http://www.nimh.nih.gov/publicat/ocdfacts.cfm. Accessed June 28, 2006.

Petruzzello SJ, Landers DM et al. A meta-analysis on the anxiety-reducing effects of acute and chronic exercise. Sports Med. 1991;11(3):143–82.

Rapkin AJ, Mikacich JA et al. The clinical nature and formal diagnosis of premenstrual, postpartum, and perimenopausal affective disorders. Curr Psychiatry Rep. 2002 Dec;4(6):419–28.

Shannahoff-Khalsa DS. An introduction to Kundalini yoga meditation techniques that are specific for the treatment of psychiatric disorders. J Altern Complement Med. 2004 Feb;10(1):91–101.

Simpson HB, Huppert JD et al. Response versus remission in obsessive-compulsive disorder. J Clin Psychiatry. 2006 Feb;67(2):269–76.

Smeraldi E, Diaferia G et al. Tryptophan depletion in obsessive-compulsive patients. Biol Psychiatry. 1996;40(5):398–402.

Taylor LH, Kobak KA. An open-label trial of St. John’s wort (Hypericum perforatum) in obsessive-compulsive disorder. J Clin Psychiatry. 2000 Aug;61(8):575–8.

Tkachuk GA, Martin GL. Exercise therapy for patients with psychiatric disorders: Research and clinical implications. Prof Psychol Res Pract. 1999;30(3):275–82.

van Grootheest DS, Cath DC, et al. Twin studies on obsessive-compulsive disorder: A review. Twin Res Hum Genet. 2005 Oct;8(5):450–8.

Whiteside SP, Port JD et al. A meta-analysis of functional neuroimaging in obsessive-compulsive disorder. Psychiatry Res. 2004 Nov 15;132(1):69–79.

Whittal ML, Thordarson DS et al. Treatment of obsessive-compulsive disorder: Cognitive behavior therapy vs. exposure and response prevention. Behav Res Ther. 2005 Dec;43(12):1559–76.